Sean Moran Net Worth

The estimated Net Worth of Sean F. Moran is at least $4.34 Million dollars as of 14 June 2024. Mr. Moran owns over 18,043 units of Corbus Pharmaceuticals Inc stock worth over $2,665,176 and over the last 16 years he sold CRBP stock worth over $52,000. In addition, he makes $1,621,300 as Chief Financial Officer at Corbus Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Moran CRBP stock SEC Form 4 insiders trading

Sean has made over 58 trades of the Corbus Pharmaceuticals Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he exercised 18,043 units of CRBP stock worth $233,837 on 14 June 2024.

The largest trade he's ever made was buying 148,960 units of Corbus Pharmaceuticals Inc stock on 17 August 2016 worth over $494,547. On average, Sean trades about 11,914 units every 76 days since 2008. As of 14 June 2024 he still owns at least 50,563 units of Corbus Pharmaceuticals Inc stock.

You can see the complete history of Mr. Moran stock trades at the bottom of the page.

Sean Moran biography

Sean F. Moran CPA serves as Chief Financial Officer of the Company. Mr. Moran joined Corbus Pharmaceuticals, Inc. (formerly JB Therapeutics), our wholly-owned subsidiary, as its Chief Financial Officer in January 2014. Mr. Moran has over twenty-five years of senior financial experience with emerging biotechnology, drug delivery and medical device companies. Mr. Moran has worked at three different companies that completed initial public offerings and maintained a listing on a public exchange. Before joining our company, Mr. Moran served as Director of Finance and then as Chief Financial Officer for InVivo Therapeutics Corporation from 2010 to 2013 and served as Chief Financial Officer of Celsion Corporation from 2008 to 2010, Transport Pharmaceuticals Inc. from 2006 to 2008, Echo Therapeutics Inc. from 2002 to 2006, SatCon Technology Corporation from 2000 to 2002, and Anika Therapeutics Inc. from 1993 to 2000. Mr. Moran is a CPA by training and earned his M.B.A. and a B.S. in Accounting from Babson College.

What is the salary of Sean Moran?

As the Chief Financial Officer of Corbus Pharmaceuticals Inc, the total compensation of Sean Moran at Corbus Pharmaceuticals Inc is $1,621,300. There are 2 executives at Corbus Pharmaceuticals Inc getting paid more, with Yuval Cohen having the highest compensation of $4,001,510.

How old is Sean Moran?

Sean Moran is 62, he's been the Chief Financial Officer of Corbus Pharmaceuticals Inc since . There are 4 older and 6 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.

What's Sean Moran's mailing address?

Sean's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.

Insiders trading at Corbus Pharmaceuticals Inc

Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor..., and Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.

What does Corbus Pharmaceuticals Inc do?

corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.

Complete history of Mr. Moran stock trades at Imunon Inc, Corbus Pharmaceuticals Inc, and InVivo Therapeutics Corp

Corbus Pharmaceuticals Inc executives and stock owners

Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Yuval Cohen,
  Chief Executive Officer, Director
• Barbara White,
  Chief Medical Officer 
• Sean Moran,
  Chief Financial Officer
• Dr. Yuval Cohen,
  CEO & Director
• Rachelle Jacques,
  Independent Director
• Sean F. Moran CPA, M.B.A., CPA, MBA,
  Chief Financial Officer
• Alan Holmer,
  Independent Chairman of the Board
• Avery Catlin,
  Independent Director
• John Jenkins,
  Independent Director
• Ted Jenkins,
  Senior Director, Investor Relations and Communications
• Peter Salzmann,
  Independent Director
• Craig Millian,
  Chief Commercial Officer
• Scott Constantine,
  Sr. Director & Head of Clinical Operations
• Christina Bertsch,
  Head of HR
• Lindsey Smith,
  Head of Corp. Communications & Patient Advocacy
• Dr. Rachael Brake Ph.D.,
  Chief Scientific Officer
• Craig Stuart Millian M.B.A.,
  Chief Operating Officer.
• David P Hochman,
  Director
• Mark Tepper,
  President and CSO
• Renu Gupta,
  Director
• George Golumbeski,
  Director
• Asset Management, Lp Cormor...,
  
• Anne Altmeyer,
  
• Yong Ben,
  
• Paris Panayiotopoulos,
  Director
• Asset Management, Lp Chen B...,
  
• Dominic Smethurst,
  Chief Medical Officer
• Sumner Burstein,
  10% owner
• Robert Paul Discordia,
  Chief Operating Officer
• Rachael Louise Brake,
  Chief Scientific Officer
• Winston Kung,